Orchid Pharma Limited has informed the Exchange about General Updates
ORCHPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Orchid Pharma has acquired 100% of a recently incorporated shelf company in Germany called Weilchensee 1272. V V GmbH, which will be renamed Orchid Pharma Europe GmbH. The target was incorporated on June 24, 2025, has a paid-up capital of €25,000, nil turnover, and no active business operations yet. Orchid paid €28,500 in cash for the full shareholding, with no related-party interest involved. The acquisition is aimed at market expansion into Europe, classified under the pharma sector. No major regulatory approvals are required except standard RBI fund remittance.
This is a small, low-cost entry into the European market via a wholly-owned subsidiary, giving Orchid a vehicle to expand into Europe. Since the target is a shell company with no current revenue, near-term financial impact is minimal, but it opens a long-term strategic channel for European business growth.